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1. Introduction 
Human growth hormone (GH), a single-chain peptide of 191 amino acids, was isolated from 
somatotroph cells of the anterior pituitary gland in 1956 and first used therapeutically for 
treatment of pituitary dwarfism in 1958 (Raben, 1958). Pituitary dwarfism is the classic form  
of growth hormone deficiency during childhood. Gigantism refers to any standing height 
more than 2 standard deviations above the mean for the person's sex, age, and Tanner stage. 
Abnormally high linear growth due to excessive action of insulin-like growth factor-I (IGF-
I)/GH causes gigantism while the epiphyseal growth plates are open during childhood, as 
puberty occurs it is followed by progressive acromegalic changes leading to a picture of a 
giant with acromegalic features - acromegalic gigantism. When onset disease is  after 
epiphyseal closure, only acromegaly results. 
Acromegaly, a somatic growth and proportion disorder first described by Marie in 1886 
(Marie, 1886). Elevated levels of growth hormone and IGF-1 are the hallmarks of this 
syndrome (Melmed, et al., 1983). When Marie first desribed this syndrome at his patients, 
pitutiary overgrowth is the cause or reflection of the visceromegaly at these patients. İn 
1909, Harvey Cushing reported the remission of clinical symptoms of acromegaly after 
partial hypophysectomy, thus indicating the etiology of the disease and its potential 
treatment as well (Cushing,  1909). 
2. Epidemiology 
It is a rare condition with a prevalence less than or equal to 70 cases per million and annual 
incidence of 3 to 4 cases per million (Alexander et al., 1980;  Ritchie et al., 1990). Acromegaly 
occurs with equal frequency in males and females. The mean age at diagnosis is 40-45 years. 
3. Pathology, etiology, pathophysiology 
GH also called somatotropin is main regulator of normal growth. Its actions responsible for 
the catching up of normal adult height. The GH gene is located on chromosome 17 (Chen et 
al., 1989). There are at least three monomeric forms of GH-the predominant physiologic 22 
kd form, a less abundant 20 kd form, and a third incompletely characterized form (Lin et al., 
1992). The principal GH form in the pituitary is a 191 amino acid, single-chain, 22 kDa 
protein (22K). It is the product coded for by the GH-N gene (N for normal) and has also 
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been termed GH-N (Parks, 1989). A second product arising from the same gene is the 20,000 
dalton GH variant (20K) (Lewis et al., 1978). This protein is identical to 22K, except for an 
internal 15 amino acid deletion (residues 32-46). 20K GH is the result of an alternatively 
spliced GH pre-mRNA where part of exon 3 is spliced out (DeNoto et al., 1981). İmportance 
of this heterogenicty is unknown. Both forms of hormone are secreted and have similar 
growth promoting activity, although metabolic effects of the 20K form are reduced. 20K has 
decreased insulin-like and perhaps slightly decreased diabetogenic activity compared to 
22K (Baumann et al., 1994). 
Once secreted from the pituitary, a substantial proportion of GH circulates bound to GH-
binding protein (GHBP) (Baumann et al., 1986; Herington et al., 1986; Leung et al., 1987). 
There are two forms of GHBP, a low-affinity variety and a high-affinity form. GHBP 
comprises the extracellular domain of the GH receptor (Leung et al., 1987)  which is located 
in peripheral tissues and mediates the effects of GH on target organs. The GH binding 
protein and GH receptor are products of the same gene. GHBP is produced by proteolytic 
cleavage of the receptor at the outer surface of target cells (Harrison et al., 1995). GH binding 
protein prolongs its half-life and regulates changes in free hormone concentration. Free 
portion can cross capillary membranes  and perform its actions.  
GH elicits intracellular signaling though a peripheral receptor and initiates a 
phosphorylation cascade involving the JAK/STAT (Janus kinase/signal transducers and 
activators of transcription)  pathway (Carter-Su et al., 1996). Liver contains most abundant 
receptors for GH. When GH receptor activated  this causes rapid JAK2 tyrosine kinase 
activation, leading to phosphorylation of intracellular signaling molecule including the 
STATs. Phosphorylated STAT proteins are directly translocated to the cell nucleus, where 
they elicit GH-specific target gene expression by binding to nuclear DNA (Xu et al., 1996). 
Growth hormone induces hepatic production of IGF-I responsible of  many of its growth-
promoting effects. Local production of IGF-I acting either in a paracrine or autocrine  
manner also has important biological effects, predominant of which is stimulating cell 
proliferation and inhibiting apoptosis (Le Roith et al., 2001). 
Secretion of GH from the pituitary is pulsatile. An  average half-life is 10-20 minutes, it is 
metabolized  through the kidneys, liver, or target tissues (Casanueva, 1992). In children and 
young adults, maximal GH secretion occurs within 1 hour after the onset of deep sleep 
(stage III or IV) (Finkelstein et al., 1972; Mendelson, 1982; Takahashi et al., 1968). Two 
hypothalamic hormones regulate GH secretion; Growth hormone releasing hormone 
(GHRH) provides the primary drive for GH synthesis and secretion by inducing GH gene 
transcription and hormone release and does not induce other anterior pituitary hormones 
(Barinaga et al., 1983; Thorner et al., 1984).  GHRH is needed for normal pulsatile GH 
secretion (Painson et al., 1991; Wehrenberg et al., 1982]. SRIF powerfully antagonizes the 
mitogenic effect of GHRH on somatotrophs, but does not inhibit GH synthesis (Billestrup et 
al., 1986), suppresses GH secretion mainly by high-affinity binding to SSTR2 and SSTR5 
receptor subtypes expressed on somatotrophs (Shimon, 1997). It is thought to be interaction 
between these two hypothalamic hormone plays a role in pulsatile GH secretion. 
Ghrelin is another  peptide of a primarily gastric origin, although ghrelin mRNA had been 
found in the hypothalamus  playing  a role in secretion of GH (Mozid et al., 2003). Synthetic 
analogues of ghrelin (GHS) had been produced as early as 25 years ago. Acute 
administration of GHS produces an immediate and massive release of GH. Co-
administration of GHS and GH-RH results in powerful GH rise that is greater than the effect 
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of either peptide administered alone (Bowers et al., 1991). GHS potentiate GH release in 
response to a maximum stimulating dose of exogenous GHRH (Penalva et al., 1993) and 
after a saturating dose of GHRH, although subsequent GHRH administration is ineffective, 
GHS remain fully effective (Jaffe et al., 1993). 
Stressful changes in the internal and external environments can produce brief episodes of 
hormone secretion. Hypoglycemia  leads to acute GH secretion, which is the basis for the 
insulin-induced hypoglycemia test, a gold standard evaluation of pituitary function (Gharib et 
al., 2003). In man, hyperglycemia causes transient GH suppression for 1 to 3 hours, followed 
by GH rise 3 to 5 hours after oral glucose administration (Roth et al., 1963). Elevation of free 
fatty acid levels is a strong inhibitor of GH release in normal humans (Imaki et al., 1985).  
Secretory episodes are induced by an increase in certain amino acids, particularly arginine 
and leucine. Neuropeptides, neurotransmitters, and opiates acts on the hypothalamus by 
affecting GHRH and SRIF release. Three hours after acute glucocorticoid administration, 
GH levels rise and remain elevated for 2 hours. Glucocorticoids administered to normal 
subjects dose-dependently inhibit GHRH-simulated GH secretion, similar to that seen in 
Cushing's syndrome (Casanueva et al., 1990). While acute glucocorticoid administration 
stimulates GH secretion, chronic steroid treatment inhibits GH. 
Activation of the gonadal system during puberty is accompanied by increased GH and IGF-
1 concentrations (Veldhuis et al., 2006; Giordano et al., 2005). Estrogen stimulates GH 
secretory rates, and testosterone increases GH secretory mass per pulse, with resultant IGF-I 
induction (Giustina & Veldhuis, 1998). 
Chronic malnutrition and prolonged fasting are associated with elevated GH pulse 
frequency and amplitude (Ho et al., 1988). The maximal GH levels occur within minutes of 
the onset of slow wave sleep (Holl et al., 1991). Emotional deprivation is associated with 
suppressed GH secretion and attenuated GH responses to provocative stimuli occur in 
endogenous depression (Sachar et al., 1972). Exercise and physical stress, including trauma, 
hypovolemic shock, sepsis increase GH levels (Vigas et al., 1977). 
Thyroid disorders also affect GH secretion. Some studies have reported several alterations 
of the GH/IGF axis and their binding proteins in hypothyroidism. The main alterations 
reported in untreated adult hypothyroid patients have been low serum concentrations of 
IGF-1 and IGFBP-3 that increase significantly with restoration of euthyroidism (Miell et al., 
1993; Valcavi et al., 1987).  
In hypothyroidism, GH pulsatility is decreased and GH responses to a number of 
secretagogues are attenuated (Valcavi et al., 1992). Fasting serum IGF-1 levels were found 
significantly lower in the subclinical hypothyroid and with levothyroxine treatment IGF-1 
concentrations were significantly increased in subclinical hypothyroid subjects (Akin et al., 
2008). Also in hyperthroidism GH responses to GHRH was found to be decreased whereas 
serum IGF-1 levels were increased (Valcavi et al., 1993). It could be expected to be decreased 
due to decreased pituitary GH contents as a result of permanent somatotrophic cell 
stimulation. At another study, hyperthyroid men is marked by a higher frequency of 
spontaneous GH secretory bursts, a higher rate of maximal GH secretion attained per burst, 
and a larger mass of GH released per burst (Iranmanesh et al., 1990). Effects of 
hyperthyroidism  on GH/IGF-1 axis are still contraversial. GH–IGF axis was not affected in 
patients with subclinical hyperthyroidism (Akin et al., 2009).  
GHRH have other actions which serve to feed back for GH secretory axis. GHRH stimulates 
SRIF secretion and inhibits further GHRH secretion in vitro (Aguila et al., 1985). SRIF 
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inhibits its own secretion in vitro (Peterfreund & Vale, 1984). GH and IGF-I feed back to 
modulate the GH axis at several levels. IGF-I acts directly on the pituitary to inhibit basal 
and GHRH-induced GH secretion and also to suppress GH gene expression (Berelowitz et 
al., 1981; Ceda et al., 1987; Ceda et al., 1985, Yamashita&  Melmed, 1986; Yamashita et al., 
1986). IGF-I also seems to have a direct hypothalamic effect, increasing SRIF secretion 
(Berelowitz et al., 1981).  
A benign somatotroph adenoma of the pituitary is the most common cause of acromegaly. 
Whether intracellular defects or excessive trophic influences from outside causes pitutiary 
tumor need to be discussed. Growth hormone-releasing hormone has trophic activity in the 
human pituitary (Thorner et al., 1982) and in addition to a case report of diffuse 
somatotroph hyperplasia in a patient with a growth hormone-releasing hormone-producing 
bronchial carcinoid (Ezzat et al., 1994). There are several cases of true somatotroph adenoma 
formation in patients with growth hormone-releasing hormone-producing hypothalamic 
gangliocytomas (Asa et al., 1984; Bevan et al., 1989). The clonality of a cellular expansion is a 
secure archaeologic tool capable of distinguishing an irreversible and potentially inexorably 
progressive process induced by an intracellular insult or insults from a relatively excessive 
but possibly reversible or self-limiting trophic response to stromal or microenvironmental 
signals (Levy, 2000; Levy, 2001). The finding of monoclonality in pituitary adenomas is 
thought to be  an evidence for the neoplastic origin of these lesions. Proto-oncogene 
activation is also a critical prerequisite for pituitary tumor formation. 
Pituitary carcinomas are another exceedingly rare cause of acromegaly. Infrequently 
acromegaly occurs as a result of a hypothalamic tumor secreting GHRH, ectopic secretion of 
GHRH from a peripheral neuroendocrine tumour (Thorner et al., 1984) or from excessive 
hypothalamic GHRH secretion (Asa et al., 1984).  
Several genetic disorders including multiple endocrine neoplasia type 1 (MEN1) syndrome, 
McCune Albright syndrome, familial acromegaly and Carney’s syndrome are also 
characterized with growth hormone excess. Postzygotic GNAS mutations result in a mosaic 
pattern of organ specificity with clinical features of McCune-Albright syndrome (OMIM 
174800), including pigmented skin lesions and polyostotic fibrous dysplasia, and endocrine 
dysfunction including precocious puberty, thyrotoxicosis, and GH and ACTH 
hypersecretion (Weinstein, 1991). 
4. Clinical features of acromegaly 
The clinical features of acromegaly are depend on high serum concentrations of both GH 
and IGF-I (Melmed, 2006). The effect of hypersomatotropism on tissue growth and 
metabolic function evolves slowly. 10 or more years may elapse from disease onset until 
diagnosis of the disease (Colao et al., 2004).  
Disease can be manifested also with signs and symptoms of pitutiary mass. Any pituitary 
adenoma  can cause headaches commonly retro-orbital. Another common symptom caused by 
the size and location of the tumor is decreased vision. This usually presents as temporal visual 
field defects. It is caused by the tumor growing upward out of the sella and pressing on the 
optic chiasm. Other findings  include diplopia, ptosis, opthalmoplegia as a result of extension 
into the cavernous sinus and compression of the cranial nerves. Sudden loss of vision 
secondary to apoplexy within the pituitary adenoma may ocur. Aggressive tumors can invade 
the roof of the palate and cause nasopharyngeal obstruction, infection and CSF leakage. 
Parinaud syndrome is caused by ectopic pinealomas most often accompanied with paralysis of 
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upward conjugate gaze. As pituitary tumors grow, they compress the pituitary gland, 
pituitary stalk and hypothalamus and interfere with normal pituitary hormone production. 
This reslts in partial or complete anterior pituitary hormone deficiency. Hypothyroidism 
syptoms, failure to lactate, decreased libido, infertility or oligo/amenorrhoea, sense of not well 
being  are common  symptoms of hypopitutiarism. Stalk compression leads to 
hyperprolactinemia. GH-secreting pituitary adenomas may also cosecrete prolactin. 
All patients with acromegaly have acral and soft tissue overgrowth, although the extent of 
the overgrowth varies. Soft tissue findings are macroglossia, large fleshy lips and nose, 
deepening of the voice, paresthesias of the hands , thickened skin, skin tags, coarsened body 
hair. Skin tags are common and may be markers for the adenomatous colonic polyps 
(Leavitt et al., 1983). These soft tissue changes may be attributed to glycosaminoglycan 
deposition and increased connective tissue collagen production (Verde et al., 1986). Hair 
growth increases and some women have hirsutism 56 percent in one series (Kaltsas et al., 
1999). Acromegalic patients may have a greater incidence of neuropathies because of 
compression of nerves by adjacent fibrous tissue and endoneural fibrous proliferation. The 
size and function of sebaceous and sweat glands increase complain of excessive perspiration 
and body odor. The heart, liver, kidneys, spleen, thyroid, parathyroid glands, and pancreas 
are larger than normal. 
Thyroid dysfunction in acromegaly may be caused by diffuse or nodular toxic or nontoxic 
goiter or Graves' disease, especially because IGF-I is a major determinant of thyroid cell 
growth (Kasagi, et al., 1999). As it can be a part of a MEN1 syndrome, hypercalcemia can 
also be seen. 
In the absence of GH there is severe atrophy of the epiphyseal plates, which become narrow 
as proliferation of cartilage progenitor cells slows markedly. 
Conversely, after GH is given to a hypopituitary subject, resumption of cellular proliferation 
causes columns of chondrocytes to elongate and epiphyseal plates to widen. Synovial tissue 
and cartilage enlarge, causing hypertrophic arthropathy of the knees, ankles, hips, spine and 
other joints (Biermasz et al., 2005). Local periarticular fibrous tissue thickening can cause 
joint stiffening, deformities, and nerve entrapment. Chondrocyte proliferation with 
increased joint space, ulcerations and fissures of weight-bearing cartilage areas, often 
accompanied by new bone formation. Chronic osteoarthritis causes narrowed and deformed 
joint space, osteophyte formation, subchondral cysts, and lax periarticular ligaments with 
ossification (Dons et al., 1988; 75 Lieberman et al., 1992). When excess GH secretion begins 
before the epiphyses of the long bones are fused, linear growth does increase; the result is 
pituitary gigantism. Skeletal overgrowth owing to periosteal new bone formation in 
response to IGF-1 (McCarthy, et al., 1989).  Subtle skeletal and acral overgrowth and soft 
tissue enlargement causes increased shoe and ring size. Mandibular overgrowth with 
prognathism, maxillary widening, teeth separation, jaw malocclusion other skeletal 
manifestations of the acromegaly. Prognathism, thick lips, macroglossia, and hypertrophied 
nasal structures can obstruct airways (Rosenow et al., 1996; Grunstein et al., 1994). This 
result in obstructive sleep apnea syndrome. Sleep apnea may also be central in origin and 
associated with higher GH and IGF-I levels ( Grunstein et al., 1994).  
Untreated acromegaly results in premature mortality, most commonly from cardiovascular 
disease (Ritchie et al., 1990; Wright et al., 1970; Etxabe et al., 1993; Rajasoorya et al., 1994; 
Orme et al., 1998). Asymmetric septal hypertrophy, left ventricular hypertrophy, 
cardiomegaly and cardiac failure develop; effective treatment reducing growth hormone 
and IGF-1 serum levels improves cardiac function (Colao et al., 1999). Heart failure occurs in 
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3 to 10 percent of patients (Damjanovic et al., 2002;  Bihan et al., 2004). An increased 
prevalence of valvular heart disease has also been reported. Arterial blood pressure (systolic 
and diastolic) is higher with loss of normal daily circadian variability (Terzolo et al., 1999). 
Hypertension was reported in approximately one third of patients who had acromegaly 
(Pietrobelli et al., 2001; Minniti et al., 1998). Insulin resistance and diabetes mellitus occur as 
a result of direct anti-insulin effects of GH (Coculescu et al., 2007; Kasayama et al., 2000). 
Several benign and malignant neoplasms, especially in the gastrointestinal tract, have been 
reported in association with acromegaly (Cheung et al., 1997; Ron et al., 1991), particularly 
colorectal tubular adenomas and carcinoma (Jenkins et al., 2001; Jenkins, 2006). It is related 
to disease activity with patients with elevated serum growth hormone and IGF-I levels 
being particularly prone to developing colonic adenomas (Jenkins et al., 2000). A compelling 
cause-and-effect relationship of acromegaly with cancer has not been established 
(Delhougne et al., 1995; Ladas et al., 1994). A recent controlled study in 161 patients revealed 
no increase in polyp incidence in acromegaly (Renehan et al., 2000). Analysis of nine 
retrospective reports (1956-1998) encompassing 21,470 person-years at risk, yielded no 
significant increased cancer incidence (Melmed et al., 2001). 
Whether patients with acromegaly are also prone to other malignancies remains 
controversial. Certainly there is epidemiological evidence in the general population that 
serum IGF-I levels in the upper part of the normal range are associated with an increased 
risk of breast and prostate cancer and some reviews have shown the former to be increased 
in acromegaly (Renehan et al., 2004; Nabarro, 1987). 
5. Molecular pathogenesis of acromegaly 
GH elicits intracellular signaling though a peripheral receptor and initiates a 
phosphorylation cascade involving the JAK/STAT (Janus kinase/signal transducers and 
activators of transcription)  pathway (Carter-Su et al., 1996). The STAT proteins become 
phosphorylated and translocate into the cell nucleus. Transcription of target proteins, such 
as IGF-I evoke pleiotropic cell responses including IGF1 synthesis, glucose metabolism, cell 
proliferation, and cytoskeletal changes.  
STAT5b is the key intracellular molecule required for GH mediation of postnatal growth, 
adipose tissue function, and sexual dimorphism of hepatic gene expression (Lanning et al., 
2006). In humans, STAT mutations result in relative GH insensitivity and growth 
retardation (Kofoed , 2003). 
6. Diagnosis 
Normal GH production from the pituitary gland is pulsatile with the maximal production 
occurring at night. Even though episodic basal growth hormone secretion patterns are 
sustained in acromegaly, diurnal variation and the sleep-related growth hormone rise are 
lost (Barkan et al., 1989). Most values of GH fall in the range of 0.1–0.2 μg/L in normal 
subjects. However there are six to ten secretory bursts during the day when GH reaches 
values of 5–30 μg/L, which may overlap with values seen in acromegalic patients. Therefore 
the only value of a random GH measurement is that of excluding acromegaly if it is 
undetectable . Unlike the largely undetectable nadir GH levels in normal subjects, those 
with acromegaly sampled over 24 hours contain detectable levels of GH (>2 μg/L) Elevated 
integrated growth hormone levels during 24-hour sampling of less than 2.5 mug/L 
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effectively exclude acromegaly (Duncan et al., 1999). The optimal way to assess the overall 
daily GH production is to obtain a mean GH over 24 h by frequent GH sampling. However, 
this method is inconvenient both for the patient and the clinician (Cordero et al., 2008). 
The current international consensus for the diagnosis of acromegaly (Giustina et al., 2000) 
recommends a nadir GH of more than 1 μg/L during an OGTT for diagnosis in conjunction 
with clinical suspicion and high IGF-1 levels. Using more sensitive newer assays, the GH 
cut-off may be even lower (Freda et al., 2003). There is a need to verify the current 
guidelines and propose lowering the current cut off for GH nadir (Costas et al., 2002; Serri et 
al., 2004). The standard OGTT consists of the administration of 75 g of glucose with GH 
measurements at various time points for up to 120 min. Normal subjects demonstrate a 
suppression of GH concentration to 2 μg/L or less throughout the 2 hours of testing 
(Chapman et al., 1994; Hattori et al., 1990). Acromegalic subjects often gives response 
paradoxically higher GH levels. Clinicians should be aware that the OGTT’s usefulness is 
limited in high catabolic states, such as stress, hepatic and renal failure, diabetes mellitus, 
obesity, pregnancy, patients on estrogen replacement or in tall adolescents in whom GH 
values may be falsely elevated (Duncan et al., 1999; Melmed et al., 2006). 
Serum sex and age-matched elevated IGF-1 levels are highly specific for acromegaly in the 
nonpregnant adult and correlate with clinical disease activity (Clemmons et al., 1979). IGF-1 
is an ideal screening test as it has a long half life of 18–20 h and the levels remain stable 
throughout the day (Giustina et al., 2000). Furthermore IGF-1 correlates with mean GH 
levels (Barkan et al., 1988) and with clinical features of acromegaly (Clemmons et al., 1979). 
Even several months after treatment when growth hormone levels are controlled, IGF-1 
serum levels may remain persistently high (Drange et al., 1999). Multiple physiologic factors 
affect IGF-1 levels and need to be taken into account when interpreting the data. IGF-1 is 
affected by age and gender (Ghigo et al., 1996) with approximately 14% decrease per decade 
during adult life (Brabant et al., 2003). Again a uniform standard for age range had not been 
established (Pokrajac et al., 2007) where serum samples with GH and IGF-1 levels close to 
the current Cortina consensus (Giustina et al., 2000) cutoffs were distributed to different 
centers to evaluate variability in assay performance. Other problems include the assay 
susceptibility to interference from binding proteins and the tendency of IGF-1 to plateau at 
mean GH levels above approximately 20 μg/L (Barkan et al., 1988). The use of exogenous 
estrogen, malnutrition, liver and renal failure decrease IGF-1 levels (Ho et al., 1922; Freda et 
al., 2003; Ho et al., 2003). On the other hand, normal pregnancy and adolescence are 
associated with elevated IGF-1 levels (Duncan et al., 1999). 
IGFBP-3 levels are also elevated. However, considerable overlap of these values with those 
in normal persons, thereby limiting the utility of this measurement. 
Magnetic resonance imaging (MRI) of the pituitary gland is the preferred imaging modality 
for diagnosis in acromegaly. An MRI provides the best assessment of tumor size, location, 
extent, and relationship to important surrounding structures and is essential for the 
neurosurgeon to adequately plan surgery and to monitor treatment. If an MRI is not 
available, a computed tomography (CT) study directed at the pituitary region may be done. 
Ectopic GHRH producing tumors may arise from bronchial and pancreatic neuroendocrine 
tumors, pheochromocytomas, pulmonary endocrine carcinomas, or rarely thymic carcinod 
(Vieira et al., 2007; Sugihara et al., 2007; Fainstein et al., 2007; Nasr et al.,2006; Bolanowski et 
al., 2006; Jansson et al., 1998). The measurement of plasma GHRH concentrations can be 
very helpful in identifying an ectopic source of GHRH in these particular cases. Total body 
scintigraphy with radiolabled somatostatin should be performed to localize the tumor and 
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to demonstrate somatostatin receptor expression by the tumor which may respond 
favorably to somatostatin analogue therapy (Kwekkeboom et al., 1993; Drange et al., 1998).  
7. Differential diagnosis 
Exclusion of an abnormality of the somatotrophic axis in a young patient with acromegaloid 
features should lead the differential diagnosis towards diagnoses such as 
pachydermoperiostosis (Hambrick et al., 1996; Rimoin, 1965; Harbison et al., 1971) or insulin 
mediated pseudoacromegaly, a disorder associated with severe insulin resistance (Flier et 
al., 1993). These nadir entities must be considered at differential diagnosis of acromegaly. 
8. Treatment   
Treatment should aim at managing the tumor mass and GH hypersecretion to prevent 
morbidity and increased mortality while preserving normal pituitary function. Complete 
surgical removal of GH-secreting tumors results in hormonal control of acromegaly and 
improvement of soft tissue changes. After successful resection, growth hormone levels 
return to normal within 1 hour, and metabolic dysfunction and soft-tissue swelling quickly 
resolve. In patients with intrasellar microadenomas, surgical removal provides biochemical 
control with normalization of IGF-I in 75–95% of patients (De et al., 2003; Ludecke et al., 
2006; Nomikos et al., 2005; Kaltsas et al., 2001; Shimon et al., 2001; Beauregard et al., 2003). 
Transsphenoidal microsurgical adenomectomy approach is used most commonly and, in the 
hands of experienced neurosurgeons, cures the majority of patients who are harboring a 
well-circumscribed microadenoma and who have serum GH levels less than 40 μg/L 
(Gittoes et al., 1999; Shimon et al., 2001; Kreutzer et al., 2001). Control rates are lower in 
patients with noninvasive macroadenomas  but even in these cases surgical removal 
provides biochemical biochemical control with normalization of IGF-I in 40–68% of patients 
(De et al., 2003; Ludecke et al., 2006; Nomikos et al., 2005; Kaltsas et al., 2001; Shimon et al., 
2001; Beauregard et al., 2003).  The success of surgery depends on the skill and experience of 
the surgeon in resecting the entire tumor without damaging normal anterior pituitary tissue. 
Craniotomy is very rarely indicated in patients with acromegaly. 
Post-transsphenoidal surgical mortality is rare and most side effects are transient. 
Permanent diabetes insipidus, cerebrospinal fluid leak, hemorrhage, and meningitis develop 
in up to 5%  and their frequency correlates with tumor size, invasiveness, and neurosurgical 
experience (Gittoes et al., 1999). In experienced hands, other complications of 
transsphenoidal surgery are rare including transient oculomotor palsies, deterioration of 
vision, carotid artery injury and epistaxis (occurring in less than 1% of patients) (Ludecke & 
Abbe , 2006; Nomikos et al., 2005). 
Dopamine agonists (DAs), somatostatin receptor ligands (SRLs), and a GH receptor antagonist 
(GHRA) are the drugs  classes available for the treatment of acromegaly. SRLs are the first-
choice pharmacotherapy for treating patients who have acromegaly. Two formulas are 
available for treatment of acromegaly octreotide  and lanreotide. Somatotroph and thyrotroph 
cells express mainly two of five SRIF receptors, SSTR2 and SSTR5 that mediate growth 
hormone and TSH secretion (Shimon & Melmed, 1998; Weckbecker et al., 2003).  
Octreotide is a short-acting somatostatin analogue that binds mainly to SSTR2 and to a 
lesser extent to SSTR5 (Lamberts, 1988). Lanreotid also acts in a same way.  Octreotide also 
exhibits some SST3 affinity (Patel, 1999). Sandostatin LAR (octreotide acetate) is a long-
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acting somatostatin analogue (Flogstad et al., 1995; Lancranjan et al., 1999) requiring 
monthly injections. Starting dose is 20-mg monthly increasing up to 40 mg depending on 
clinical and biochemical responses. Depot preparation of lanreotide delivered as an 
aqueous, small-volume mixture (60, 90, or 120 mg) in prefilled syringes for deep 
subcutaneous administration every 28 days (Biermasz et al., 2005). 
Most studies assessing SRLs efficacy in acromegaly define disease control by mean fasting 
random serum GH levels less than 2.5 μg/L or normalization of age- and gender-matched 
IGF-1 plasma levels .Treatment with depot form of lanreotide (60 mg every 21 or 28 days) 
reduced GH less than 2.5 μg/L in 76% of patients (Attanasio et al.,2003; Ambrosio et al., 
2002). In another study, monthly injections sandostatin for 9 years reduced integrated serum 
GH levels to less than 2 μg/L in more than 75% of patients (Cozzi et al., 2006). More than 
70% of patients experience improved general well-being, and soft tissue swelling dissipates 
within several days of treatment (Ezzat, et al., 1992). Headache, a common symptom in 
acromegaly, usually resolves within minutes of injection (Pascual et al., 1991) reflecting a 
specific central analgesic effect. 
Joint function and crepitus improve, ultrasound shows evidence of bone or cartilage repair, 
and after several months, sleep apnea improves (Colao et al., 2004). Asymptomatic patients 
experience a significant decrease of blood pressure, heart rate, and left ventricular (LV) wall 
thickness (Colao et al., 2000). 
SRLs are effective also in reducing tumor size. Significant tumor size decrease has been 
reported in 52% of patients on primary therapy (Bevan et al., 2005). A critical analysis of 14 
studies reported that 37% of patients treated primarily by SRL experience significant tumor 
shrinkage (Melmed et al., 2005). 
In vivo octreoscan imaging visualizing SRIF receptors demonstrates that GH responsiveness 
directly correlates with the abundance of pituitary receptors, and patients resistant to 
octreotide do not have visible receptor binding sites (Ur et al., 1992). Efficacy of octreotide 
action is determined by frequency of drug administration, total daily dose, tumor size, 
densely granulated tumors (Bhayana et al., 2005) and pretreatment GH levels. 
The use of SRLs is most appropriate; as first-line therapy when there is a low probability of a 
surgical cure (Melmed et al., 2005; Cozzi et al., 2006; Maiza et al., 2007; Mercado et al., 2007; 
Colao, et al., 2006) after surgery has failed to achieve biochemical control, before surgery to 
improve severe comorbidities that prevent or could complicate immediate surgery (Carlsen 
et al., 2008) to provide disease control, or partial control in the time between administration 
of radiation therapy and the onset of maximum benefit attained from radiation therapy 
(Melmed et al., 2009). Gastrointestinal symptoms including  nausea, mild malabsorption, 
flatulence, diarrhea or constipation are common mild side effects of SRLs. Multiple small 
gallstones and gallbladder sludge may occur, occasionally result in cholecystitis. Abnormal 
glucose metabolism is described with the use of SRLs, as activation of SST2 and SST5 in the 
pancreatic insulin-secreting beta cells likely inhibits insulin secretion and counter-regulatory 
hormones, such as glucagon. Mild hyperglycemia and, rarely hypoglycemia (Bruttomesso et 
al., 2001) manifest mostly in patients who have pre-existing glucose abnormalities. 
Octreotide can interact with several drugs including cyclosporine. Absorption of oral 
hypoglycemic agents, ǃ-blockers, calcium channel blockers can be change and dosage 
titration should be made slowly with SRL at patients using these agents.  Asymptomatic 
sinus bradycardia can also be seen with these drugs. 
Only cabergoline has any efficacy in acromegaly, and this is limited monotherapy  effective 
in less than 10% of patients (Bevan et al., 1992; Colao et al., 1997; Abs et al., 1998; Cozzi et al., 
1998). Patients with hyperprolactinemia and minimal GH elevation might benefit most from 
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dopamine agonist treatment. Main usages of DAs are; when the patient prefers oral 
medication, after surgery in selected patients, such as those with markedly elevated 
prolactin and/or modestly elevated GH and IGF-I levels (Melmed et al., 2009) as additive 
therapy to SRL therapy in patients partially responsive to a maximum SRL dose  (Wagenaar 
et al., 1990; Sadoul et al., 1992; Cremonini et al., 1992; Marzullo et al., 1999; Cozzi et al., 2004; 
Selvarajah et al., 2005). Side effects of DAs include gastrointestinal discomfort, transient 
nausea and vomiting, nasal congestion, dizziness, postural hypotension, headache, and 
mood disorders (Colao et al., 1997). It is known that increased incidence of valvular heart 
disease with high doses of carbegoline. 
GH action through the surface membrane GH receptor is mediated by ligand-induced 
receptor signaling. The postreceptor GH signal is not elicited if the receptor is bound by 
pegvisomant, a GH-receptor antagonist, which blocks subsequent IGF-I generation (Trainer, 
et al., 2000). Daily pegvisomant (20 mg) given for 12 weeks, normalized IGF-1 levels in 82% 
of patients who had acromegaly (Kopchick et al., 2002). The indications for its use are; in 
patients that have persistently elevated IGF-I levels despite maximal therapy with other 
treatment modalities, possibly as monotherapy or in combination with a SRL in other 
patients (Melmed et al., 2009).  
 Because elevated hepatic transaminases have been reported (Biering et al., 2006) liver 
enzymes should be measured every 6 months. Serum GH levels are increased as much as 
76% over baseline levels and persistent tumor growth is reported (Trainer et al., 2000) even 
though, in most cases, GH-secreting adenoma volumes do not change (Van der Lely et 
al.,2001; Barkan et al., 2005). Current recommendations are to perform a pituitary MRI every 
6 months in all patients (Melmed et al., 2006). 
Primary or adjuvant radiation of GH-secreting tumors may be achieved by conventional 
external deep X-ray therapy, proton beam, or gamma knife radiation surgery. It is usually 
reserved for patients who have postoperative persistent or recurrent tumors that are 
resistant or intolerant to medical treatment may benefit from radiotherapy.After 
conventional radiation (up to 5000 rads divided in 180-rad fractions over 6 weeks), tumors 
cease growing and shrink in most of patients (Biermasz et al., 2000). Conventional 
radiotherapy (conformal fractionated radiotherapy) can lower GH levels and normalize IGF-
I in over 60% of patients, but maximum response is achieved 10–15 yr after radiotherapy is 
administered (Barrande et al., 2000; Jenkins et al., 2006; Minniti et al., 2005). 
Stereotactic radiosurgery using gamma knife delivers a single tumor-focused radiation 
fraction. Five-year remission rates with gamma knife radiotherapy in patients with acromegaly 
(after surgical debulking) range from 29 to 60% (Attanasio et al., 2003; Castinetti et al., 2005; 
Jezkova et al., 2006; Pollock et al., 2007). After 10 years, about half of all patients receiving 
radiation therapy have signs of pituitary trophic hormone disruption, and this prevalence 
increases annually thereafter.  Side effects of conventional radiation including hair loss, cranial 
nerve palsies, tumor necrosis with hemorrhage, and loss of vision or pituitary apoplexy (both 
rare) have been documented in up to 2% of patients (Van der Lely, 1997). Lethargy, impaired 
memory, brain tumors at irradiation site and personality changes can also occur. 
9. Posttreatment follow-up 
GH and IGF-I should be measured to assess the biochemical response to any medical 
treatment. OGTT and IGF-1 measurement wit clinical examination should be performed at 
3–6 months after surgery, and 3-4 months period thereafter. If patient receivig pegvisomant, 
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monitoring should be made with only IGF-1. OGTT is not helpful in monitoring therapeutic 
responses while patients are receiving SRL therapy (Arafat et al., 2008; Carmichael et al., 
2009). Biochemical control is generally defined as a normal IGF-I for age and gender and age 
less than 1.0 ng/ml during an OGTT. After biochemical control is achieved, follow up of 
patients can be made semiannually. With usage of more sensitive GH level less than 0.4 
ng/ml thought to be consistent with remission. Pituitary MRI shhuld be performed 
annually, especially at patients having residual tumor and medical treatment. 
Colonoscopy should be performed at three- to four-year intervals in patients over 50 years 
old and in those with more than three skin tags for early detection and treatment of 
premalignant colonic polyps (Melmed, 2002). At follow up patients should be evaluated 
periodically for cardiovascular, skletal, dental problems. 
10. Future prospects of acromegaly 
Bogazzi et al. (Bogazzi et al., 2004) reported that thiazolidinedione treatment might slow 
down the growth of well-established GH-secreting tumors and might effectively reduce the 
GH hypersecretion. In a study, rosiglitazone, used at maximum approved dosage, did not 
reduce plasma GH and IGF-1 levels in patients with acromegaly (Bastemir et al., 2007 ). 
In recent years, molecular studies investigated the possible association of gene 
polymorphisms and susceptibility to diseases. Recently, a polymorphism in the promotor 
region of the IGF-I gene which is associated with IGF-I serum levels, birthweight and body 
height in adults has been identified (Vaessen et al., 2001; Rietveld et al., 2004). 194 bp allele 
(20 CA repeats) of the IGF-I promoter have higher circulating IGF-I levels than others. The 
patients with 194 bp genotype are the resistant patients with active disease and they 
required high dose medication responsible from resistance to drugs (Akin et al., 2010). The 
angiotensinojen MT and AT1R CC1166 genotype carriers may have more risk than other 
genotypes in the development of hypertension in acromegaly (Turgut , et al., 2011). 
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